Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 3 1Phase 1/2 1

Status

Withdrawn 1Terminated 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Polyps 1Fatigue 1Colorectal Neoplasms 1Colonic Neoplasms 1

Interventions

Cisplatin 1041Cyclophosphamide 973Carboplatin 954Radiotherapy 893Bevacizumab 847Gemcitabine 817pembrolizumab 759Paclitaxel 738Docetaxel 734Oxaliplatin 706Capecitabine 648Fluorouracil 564Rituximab 559Nivolumab 506Dexamethasone 487Etoposide 468Doxorubicin 458Irinotecan 442Drug Therapy 402Leucovorin 377Cytarabine 342Cetuximab 340Lenalidomide 326Trastuzumab 323Pemetrexed 315durvalumab 295Filgrastim 287Magnetic Resonance Spectroscopy 278Temozolomide 275Prednisone 273

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 2 × OTHER × eicosapentaenoic acid ethyl ester × Clear all
NCT03661047 2021-11-17

OMICC

Massachusetts General Hospital

Phase 2 Withdrawn
Gastrointestinal

Colonic Neoplasms, Polyps, Colorectal Neoplasms

NCT02940223 2021-06-10

Ethyl Icosapentate and Physical Activity in Treating Fatigue in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2 Terminated
2 enrolled 6 charts

Fatigue

Data powered by HemOnc (CC BY 4.0) Colophon âš¡